These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30704313)

  • 1. Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.
    Cattaneo D; Capetti A; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):245-252. PubMed ID: 30704313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
    Bollen P; Reiss P; Schapiro J; Burger D
    Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.
    Scott LJ
    Drugs; 2020 Jan; 80(1):61-72. PubMed ID: 31865558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
    Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
    Boswell R; Foisy MM; Hughes CA
    Ann Pharmacother; 2018 Jul; 52(7):681-689. PubMed ID: 29442543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
    Allavena C; Volteau C; André-Garnier E; Guimard T; Hall N; Khatchatourian L; Morrier M; Billaud E; Rodallec A; Reliquet V; Jovelin T; Le Guen L; Perré P; Grégoire M; Raffi F
    Med Mal Infect; 2019 Oct; 49(7):505-510. PubMed ID: 30583867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
    Capetti AF; Astuti N; Cattaneo D; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV.
    Cattaneo D; Cossu MV; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):927-935. PubMed ID: 31668105
    [No Abstract]   [Full Text] [Related]  

  • 14. Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
    Ciccullo A; Baldin G; Borghetti A; Di Giambenedetto S
    Expert Rev Anti Infect Ther; 2020 Apr; 18(4):279-292. PubMed ID: 32067525
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Chandasana H; Singh R; Adkison K; Ait-Khaled M; Pene Dumitrescu T
    Antimicrob Agents Chemother; 2024 May; 68(5):e0150423. PubMed ID: 38587380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
    Brizzi MB; Chiampas TD; Michienzi SM; Young JD; Patel MC; Badowski ME
    Int J STD AIDS; 2019 Oct; 30(12):1163-1168. PubMed ID: 31558124
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
    Baldin G; Ciccullo A; Rusconi S; Madeddu G; Sterrantino G; Freedman A; Giacometti A; Celani L; Latini A; Rossetti B; Cossu MV; Giacomelli A; Lagi F; Capetti A; Di Giambenedetto S
    Infez Med; 2019 Dec; 27(4):410-414. PubMed ID: 31846991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir, abacavir and lamivudine as HIV therapy.
    Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
    Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preclinical discovery and development of dolutegravir for the treatment of HIV.
    Bailly F; Cotelle P
    Expert Opin Drug Discov; 2015; 10(11):1243-53. PubMed ID: 26517818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.